CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameCD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing)

Drug Alias NameCD19 hsCAR-TCD19特异性嵌合抗原受体T细胞疗法CD19-specific chimeric antigen receptor engineered T cells抗CD19人源化嵌合抗原受体T细胞疗法

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesXuanwu Hospital Of Capital Medical University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesXuanwu Hospital Of Capital Medical University

Active IndicationsN/A

Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A